Experimental cell therapy targets deadly childhood brain cancer
NCT ID NCT03396575
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 participants) and was terminated early, so it is unclear how well it works, but researchers were checking for safety and immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TTRNA-DC vaccines with GM-CSF and TTRNA-xALT T cells
What this could lead to
If it works, this could point toward a new treatment approach for DIPG, a rare and deadly childhood brain cancer.
What could go wrong
This was a very early, small Phase I trial that was terminated early, so results are limited. The treatment involves strong chemotherapy and cell therapy, which can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN STEM GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UF Health Shands Children's Hospital
Gainesville, Florida, 32610, United States